novo nordisk metsera - Search News

Pfizer acquires Metsera in $10 billion deal

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits

By Rishabh Jaiswal, Sabrina Valle and Maggie Fick NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk.

· 3d · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Analytics Insight · 32m

Pfizer to Acquire Metsera in $10 Billion Weight-Loss Drug Deal, Surpassing Novo Nordisk

Devdiscourse

Novo Nordisk's Bold Move: The Fierce Battle for Metsera Unfolds

Novo Nordisk's $10 billion bid for Metsera, an obesity drug developer, is embroiled in legal scrutiny over potential U.S. antitrust law violations. As Pfizer and Novo vie for Metsera, the FTC warns of ...

BioSpace

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Pfizer acquires Metsera in $10 billion deal

Novo Nordisk's Bold Move: The Fierce Battle for Metsera Unfolds

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

Trending now